Art has over 40 years of experience as a pharmaceutical industry executive and venture capital investor in life science companies. Art founded Pappas Capital in 1994, and over the past twenty-seven years the firm has managed more than $540 million in capital and invested in more than 85 companies.
Art currently serves as a director for Sorriso Pharmaceuticals and OrphoMed, and as a board observer for Real Endpoints. Prior to founding Pappas Capital, Art held senior leadership positions at Glaxo Holdings, Abbott International, Merrell Dow Pharmaceuticals and the Dow Chemical Company. He previously served as Chairman for CoLucid Pharmaceuticals, as a director for Aura Biosciences, Reneo Pharmaceuticals, Afferent Pharmaceuticals, Arix Bioscience, Chimerix, TYRX, Quintiles Transnational Corp., Syntonix Pharmaceuticals, LEAD Therapeutics and Embrex; and as a board observer for Amplyx Pharmaceuticals, Balance Therapeutics, Kezar Life Sciences, Milestone Pharmaceuticals and Plexxikon.
Art holds various director, trustee and advisor positions for the North Carolina Biotechnology Center, the Medical University of South Carolina Foundation for Research Development, The Wistar Institute, the Ronald McDonald House of Durham & Wake, the Duke Cancer Institute, and the BioExec Institute. Art is a decorated Vietnam veteran, having served as an officer in the US Army 101st Airborne Division and with 2nd PSYOP Airborne JFK Special Warfare. Art received a BS in biology from The Ohio State University and an MBA in finance from Xavier University.